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Several approaches have been developed to improve or replace the only available vaccine
for tuberculosis (TB), BCG (Bacille Calmette Guerin). The development of subunit protein
vaccines is a promising strategy because it combines specificity and safety. In addition,
subunit protein vaccines can be designed to have selected immune epitopes associated
with immunomodulating components to drive the appropriate immune response. How-
ever, the limited antigens present in subunit vaccines reduce their capacity to stimulate a
complete immune response compared with vaccines composed of live attenuated or killed
microorganisms. This deficiency can be compensated by the incorporation of adjuvants in
the vaccine formulation. The fusion of adjuvants with Mycobacterium tuberculosis (Mtb)
proteins or immune epitopes has the potential to become the new frontier in the TB vac-
cine development field. Researchers have addressed this approach by fusing the immune
epitopes of their vaccines with molecules such as interleukins, lipids, lipoproteins, and
immune stimulatory peptides, which have the potential to enhance the immune response.
The fused molecules are being tested as subunit vaccines alone or within live attenuated
vector contexts. Therefore, the objectives of this review are to discuss the association of
Mtb fusion proteins with adjuvants; Mtb immunogens fused with adjuvants; and cytokine
fusion with Mtb proteins and live recombinant vectors expressing cytokines. The incorpo-
ration of adjuvant molecules in a vaccine can be complex, and developing a stable fusion
with proteins is a challenging task. Overall, the fusion of adjuvants with Mtb epitopes,
despite the limited number of studies, is a promising field in vaccine development.
Keywords: fusion, adjuvant, peptides, protection
INTRODUCTION
It is undeniable that vaccination is the best strategy available to
efficiently control infectious diseases. For instance, the eradica-
tion of several infectious diseases concomitant to the lowering
of morbidity and mortality rate of others can currently only be
achieved by vaccination strategies. However, in the case of tuber-
culosis (TB), the development of a vaccine (Mycobacterium bovis
BCG) did not have the capacity to eradicate the illness, and it per-
sists as the second leading cause of deaths by infectious diseases,
behind only AIDS (1, 2). Consequently, efforts have been made
to develop vaccines that will improve or replace BCG, with the
capacity to avoid infection and prevent the development of any
of its disease forms and that is safe among immunocompromised
individuals and capable of eliciting a protective immune response
by several cellular populations (3).
Among the most promising strategies are the protein sub-
unit vaccines that present desirable qualities for a vaccine, which
are specificity, safety, and easy production (4). Protein subunit
vaccines have been shown to induce a Th1 immune response,
which is classically the response primarily associated with pro-
tection against TB. Such a response is characterized by the pro-
duction of cytokines such as gamma interferon (IFN-γ), which
is responsible for macrophage activation; tumor necrosis factor
alpha (TNF-α), which is important for granuloma development
and maintenance; and interleukin 2 (IL-2), which is responsible
for the clonal expansion of T lymphocytes and is thus involved in
immune response maintenance (5, 6). Due to these characteristics,
several protein subunit vaccines are currently in advanced clinical
trials (3, 7).
The selection of protein subunit vaccine components is based
on the knowledge of which of the microorganism’s molecules are
capable of eliciting a protective immune response (8). Therefore,
due to the high level of complexity involved in the interaction
between Mycobacterium tuberculosis (Mtb) and its host, the under-
standing of the bacteria’s immunogenic repertoire is of utmost
importance for the development of an efficient vaccine. Antigens
that are recognized by the host cells during active TB, when the
bacilli are replicating, or during latent infection as well as those
involved in the immunologic evasion mechanisms or the elicita-
tion of CD4+ and CD8+ specific T cells are potential targets for
immunologically controlling infections (3, 7). As the selection of
potential proteins is not easy due to the vast number of MHC
polymorphisms, it is necessary to select or design proteins that
present promiscuous epitopes (9). Thus, the capacity of a single
protein to induce an efficient immune response is inferior to other
vaccine strategies (e.g., attenuated and viral vector vaccines), and
their utilization is strictly associated with the use of adjuvants and
immunomodulators (4, 10, 11).
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Adjuvants, in the context of vaccines,are defined as components
capable of enhancing and/or shaping antigen-specific immune
responses (12). They can be divided into two classes: vehicles,
which present vaccine antigens to the immune system in a more
efficient way and control the release and storage of antigens to
increase the specific immune response; immunostimulants, which
affect the immune system and increase the immune responses to
antigens (13). An adjuvant to be used in a vaccine against TB must
have the capacity to support the generation of a robust and lasting
Th1 type response. Few adjuvants are licensed to use in human
vaccines, and the majority of them are poor inducers of Th1
type responses (squalene-based emulsions and aluminum-based
salts). Currently, several investigations have been conducted with
the objective of developing new adjuvants, many of which have
searched for adjuvants that are capable of eliciting a Th1 immune
response. One of these approaches is the incorporation of mole-
cules that are capable of interaction with the pattern recognition
receptors (PRRs) used by the innate immune system to recognize
pathogen-associated molecular patterns (PAMPs), which are mol-
ecules or motifs that are conserved and present exclusively among
pathogens (14).
Given the distinct biochemical properties of PAMPs (pepti-
doglycan, flagellin, lipopolysaccharide, teichoic and lipoteichoic
acids, mannose residues, CpG DNA, and single-stranded RNA,
among others), several types of receptors have been described
[toll-like receptors (TLRs), RIG-1, NOD, and scavengers for
example]. The TLR family is the most abundant and diversi-
fied and present on antigen-presenting cells (APCs) and many
other cell types not related to the immune system. Signaling
through TLRs can result in two possible cascades: the first is
dependent on the molecule MYD88 (for myeloid differentiation
factor 88) and related to TLR1, TLR2, TLR4, TLR5, TLR6, TLR7,
TLR8, and TLR9; the second is dependent on TIF (TIR-domain-
containing adaptor-inducing interferon-β) and is associated with
TLR3 and TLR4 (15). The recognition of PAMPs by TLRs can
result in the expression of co-stimulatory molecules such as CD40,
CD80, and CD86 as well as the expression of pro-inflammatory
cytokines (IL-1, IL-6, IL-8, IL-12, TNF-α, COX-2, and type 1
interferons) that collectively are related to the development of
an adaptive immune response by both B and T lymphocytes (16)
(Figure 1).
To improve the number of epitopes associated with a specific
vaccine, fusions of different proteins are being developed. Vaccines
based on fusion proteins have specific bacterial protein antigens
comprised of proteins with better immunogenic capacities than
vaccines composed of a single protein. However, this approach
is not sufficient to induce a desired immune response, and sev-
eral molecules with potential immunogenic properties are needed
in association with fusion proteins. In this regard, the fusion of
Mtb antigens to PAMPs (17–20), damage-associated molecular
patterns (DAMPs) (21), and/or to interleukins [Table 1; Ref. (22–
26)] enhances the innate immune system response, increases the
capacity of the antigen to stimulate higher production of cytokines
and chemokines, and elicits distinct cell populations that will aid
in the defense against the bacteria (Table 1). This review covers
publications that used different strategies to fuse Mtb antigens
with adjuvants or with molecules with the capacity to interact and
stimulate the immune system, addressing their immunogenicity
and protection outcomes in vaccine models.
ASSOCIATION OFMtb FUSION PROTEINS WITH ADJUVANTS
Some protein subunit vaccines against TB that are currently in
clinical trials also use adjuvant molecules that are TLR agonists.
The fusion Mtb72 [a protein fusion containing the antigens Mtb32
(Rv1196) and Mtb39 (Rv0125)] uses the adjuvants AS01B™(a
liposomal formulation) and AS02A™(an oil-in-water emulsion)
was developed by GlaxoSmithKline (GSK). The abovementioned
adjuvants are composed of MPL (3-deacylated monophosphoryl
lipid A) and the detergent QS-21. MPL is a detoxified derivative
of lipid A from the Gram-negative bacteria Salmonella minnesota
R595 LPS, while QS-21 (fraction 1) is a substance purified and
fractionated from the bark of the South American tree Quillaja
saponaria. The known action of MPL is through TLR4, whereas
QS-21 has no related TLR agonistic action (27). In animal studies
(mice and guinea pigs), vaccination with Mtb72F and the adjuvant
AS01B proved to be protective, with strong induction of antibodies
(IgG1 and IgG2) and enhanced production of IFN-γ by CD4+ T
cells and cytotoxic activity by CD8+ T cells. Although the vaccine
formulation using AS02A induced weaker immune responses, they
were able to diminish the Mtb bacillary load in mice. In clinical tri-
als that compared M72 (Mtb72f with three point mutations aiming
to improve antigen processing and enhance protein expression) in
combination with AS01B or AS02A, both vaccine formulations
were shown to be safe and immunogenic, with memory cell gen-
eration (persistency was followed for 3 years) and the production
of cytokines protective against Mtb by several cell populations,
generating similar immune responses (28–30).
Two other fusion proteins (Hybrid 4 and Hybrid 56), which
are currently in clinical trials, are combined with the adjuvant
IC31™. This adjuvant is made of two components, a TLR9 agonist
(the oligodeoxynucleotide ODN1a) and an artificial antimicrobial
cationic peptide (KLKL5KLK), which serves as a vehicle. Its mech-
anism of action is related to TLR activation within endosomes, and
as such, IC31 is a good adjuvant for use in vaccines against intracel-
lular microorganisms. This adjuvant was shown in several animal
models to aid the skewing of the immune response toward Th1 and
Th17, which is most likely associated with its adjuvant effect on
dendritic cells, enhancing the expression of co-stimulatory mol-
ecules (CD80, CD86, and CD40) and the expression of IL-12p40
(31, 32).
The vaccine ID93, created by the fusion of epitopes from
Rv3619, Rv1813, Rv3620, and Rv2608 and proposed to improve
TB prophylaxis, includes GLA-SE [a glucopyranosyl lipid (TLR4
agonist) in a stable emulsion] as an adjuvant. Baldwin et al. (33)
reported that protection was associated with strong stimulation of
Th1 type immune responses, with an increase in polyfunctional
cells (producing IL-2, TNF-α, and IFN-γ). This vaccine approach
was shown to boost BCG protection and diminish multi-drug
resistant Mtb infection in mice, guinea pigs, and cynomolgus mon-
keys (34). A peptide fusion associated with a strong adjuvant that
is only mixed with the recombinant protein just before the injec-
tion might be a stimulator of the BCG immune response elicited
during childhood. To select the best adjuvant to combine with
ID-93-GLA, different formulations including this TLR4 agonist
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FIGURE 1 | Molecular mechanisms of the adjuvant molecules
reviewed. Adjuvants are molecules that promote inflammatory reactions,
interacting with the innate immune system and assisting in the generation
of adaptive immune responses. PAMPs interact primarily with TLR2
(lipoproteins and Pam2Cys) and TLR5 (flagellin). DAMPs (e.g., Hsp70) can
be recognized by many molecules of the immune system, but the innate
immune system interacts with Hsp70 primarily through TLR4. Adjuvants
lead to the generation of intracellular signaling cascades (dependent on
MyD88 and TRIF) that culminate with the production of pro-inflammatory
cytokines. The cytokines then act as the third signal, aiding the
development of the adaptive immune response in combination with the
presentation of the fused antigen (first signal). Effector (e) and memory (m)
cells are generated upon antigen presentation. Some cytokines induced by
the adjuvants or used as adjuvants, such as IL-2, IL-12, IL-15, and GM-CSF,
are important for activation of the protective immune response or to
maintain a long-lasting immune response (memory). Among the T cell
subsets induced during vaccination, Th1 cells (which produce IL-2, IFN-γ,
and TNF-α) can stimulate macrophages (MΦ) and Th17 cells (which produce
IL-17) activate primarily polymorphonuclear cells (PMNs), and these have
been directly associated with protection against Mtb. Some adjuvants also
induce antigen presentation via MHC-I and thus activate CD8+T cells,
which differentiate into cytotoxic cells (CD8tc) and act on infected (MΦi) or
effector cells (CD8e) to secrete cytokines and differentiate into memory
cells (CD8m).
have been tested, including water with aluminum salts, emulsions,
and liposomes. The best formulation was prepared in an aqueous
nanosuspension containing alum (35). However, further studies
should be conducted to best define the adjuvant associated with
protective immune responses and the eradication of the bacilli
from the host.
Although not an adjuvant currently in clinical trials, TDB
(trehalose-6,6-dibehenate) has drawn attention because it is a
less toxic analog of TDM (trehalose-6,6-dimycolate), a critical
component of the cell wall of Mtb. TDB arose from changes
in TDM, also known as cord factor, which is a potent inducer
of Th1 type responses with restricted use in humans because
of its toxicity. The effect of TDB was evaluated with the
H1 fusion protein (Ag85B-ESAT-6) and shown to be a pow-
erful aid in stimulating the cellular response of Th1 and
Th17 populations as well as humoral immune responses (36,
37). The Mincle receptor (a C-type lectin) is responsible for
the recognition of TDB (38) and TDM (39). It has been
demonstrated that the association of Mincle–Fcrγ–Syk–CARD9
is involved in the response to TDM/TDB to generate Th1 and
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Table 1 | Reviewed studies that evaluated fusions ofM. tuberculosis antigens with adjuvant molecules: molecules used and the generated
immune response.
Reference Antigen Adjuvant Elicited response
Antibodies Cytokines CD4+ CD8+ Memory Protectiona
(18) ESAT-6 26 kDa
lipoprotein
N IL-12p40 ↑ IFNγ ↑ N N =
(20) HspX91–110 Pam2Cys N IL-6 ↑, IL-12 ↑,
IFNγ ↑
CD4+ IFNγ+ ↑ N CD44hi CD62hi ↑ ↑
CD44hi CD62lo ↑
(17) Ag85A OprI
lipoprotein
IgG ↑, IgG2a ↑ IL-2 ↑, IFNγ ↑,
IL-10 ↑
N N N =
(19) PPE 27 kDa Flagellin IgG1 ↑, IgG2a
↑, IgG2b ↑
IFNγ ↑ N N N N
(21) ESAT-6 C-terminal
Hsp70
IgG ↑ IFNγ ↑, IL-4 ↑ N N N N
(24) Hsp65 IL-2 IgG ↑ IFNγ ↑, IL-2 ↑ N CTL ↑ N =
(22) ESAT-6 IL-2 IgG ↑ IFN-γ ↑ N CTL ↑ N N
(25) ESAT-6 IL-12p70 IgG ↑, IgG1 ↑,
IgG2a ↑
IFN-γ ↑ CD4+↑ CD8+↑ N ↓
(23) Ag85B IL-15 N IFN-γ ↑ CD4+ IFNγ+ ↑
CD4+ CD44+↑
CD8+ IFNγ+ ↑
CD8+ CD44+↑
CD4+ CD44+
CD62+↑, CD8+
CD44+ CD62+↑
↑
(26) ESAT-6 GM-CSF IgG ↑, IgG1 ↑,
IgG2a ↑1
IFN-γ ↑,
GM-CSF ↑
CD4+ ↑ CD8+ ↑ N N
aProtection compared to BCG.
N, not evaluated; =, equal, ↑, higher; ↓, lower.
Th17 type immune responses in addition to activating the Nlrp3
inflammasome, inducing the production of IL-1β (40, 41).
Mtb IMMUNOGENS FUSED WITH ADJUVANTS
The cell wall of Mtb is a great source of PAMPs, as TLR2 is respon-
sible for recognizing most of the mycobacterial lipid antigens such
as lipoproteins, lipoarabinomannan (LAM), and other glycolipids.
In addition to its pro-inflammatory action, TLR2 activation can
result in the production of cathelicidin, a peptide with micro-
bicidal function that also acts against intracellular bacteria (42,
43). To effectively recognize these molecules, TLR2 forms het-
erodimers with TLR1 and TLR6. Normally diacetylated molecules
are recognized by the TLR2/TLR6 heterodimer, while triacetylated
molecules (the majority are found in Gram-negative bacteria and
mycobacteria) and LAM are recognized by the TLR2/TLR1 het-
erodimer. However, this recognition scheme is not mandatory
because the recognition of lipoproteins depends both on their
acetylation as well as on the peptide chain (44–46). In addition,
the recognition of TLR2 agonists is also affected by accessory mole-
cules, including CD14, CD36, lipopolysaccharide-binding protein,
and others (42, 47, 48).
One of the molecules capable of interacting with TLR2 is
the 26 kDa lipoprotein (Rv1411) whose recognition is related to
increased production of IL-12, which in turn stimulates T lym-
phocytes and NK cells to produce and secrete IFN-γ, the most
important inducer of reactive oxygen and nitrogen species, which
are key effector molecules to kill the bacilli (49) (Figure 1). To
take advantage of the Th1 immune response-boosting effects pro-
vided by the 26 kDa lipoprotein, this protein was fused to another
immunodominant Mtb antigen, ESAT-6, to form the fusion pro-
tein CSU-F36. This recombinant fusion protein was produced
in Mycobacterium smegmatis, a non-pathogenic mycobacterial
species that is capable of glycosylation and acylation, allowing the
molecule to be recognized as a PAMP and to correctly interact with
TLR2. This protein fusion was tested in C57BL/6 mice and proved
to be capable of inducing strong IL-12 p40 expression, stimulating
CD4+ IFN-γ+ lymphocytes and inducing protection similar to
BCG in a murine model of infection [Table 1; Ref. (18)].
Another TLR2 agonist, S-[2,3-bis(palmitoyloxy)propyl]-
cysteine (Pam2Cys), has also presented favorable characteristics
for a fusion vaccine against TB. Pam2Cys is a potent dendritic cell
stimulator and has the ability to induce antigen cross-presentation.
This synthetic molecule was derived from mycoplasma MALP-2
(macrophage-activating lipopeptide) (50). When a promiscuous
peptide (capable of binding to several MHC clefts) from the 16 kDa
heat shock protein (HSP) (amino acids 91–110) was fused to
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Pam2Cys to generate L91, it was observed that this fusion was
able to induce dendritic cell maturation by enhancing the expres-
sion of the co-stimulatory molecules CD40, CD80, and CD86
and by stimulating the production of IL-6 and IL-12. The immu-
nization of mice with L91 was capable of inducing a strong Th1
response, as evidenced by the increase of IFN-γ-producing CD4+
T cells as well as memory CD44hi CD62Lhi (central memory) and
CD44hi CD62Llo (effector memory) CD4+ T cells. Last, L91 was
more capable than BCG of protecting vaccinated guinea pigs from
Mtb challenge by reducing the bacterial load and the pathology
[Table 1; Ref. (20)].
The outer membrane lipoprotein (OprI) of Pseudomonas
aeruginosa can bind to TLR3/TLR4, and it has been demonstrated
to be capable of supporting a strong Th1 response with the pro-
duction of IFN-γ and TNF-α as well as the induction of IgG2a
in a Leishmania major model of infection (51). P. aeruginosa
OprI was fused to antigen 85A (Ag85A) from Mtb and intro-
duced in Escherichia coli, which has the machinery necessary to
N-acylate OprI. This fusion was used in a prime-boost strategy
following vaccination with Ag85A DNA or BCG. The intranasal
administration of the fusion with the DNA vaccine enhanced the
immune response by potentiating the production of antibodies
against Ag85A and enhancing IL-2- and IFN-γ-producing cells,
but it was not able to improve its protective capacity. Similarly,
the OprI-Ag85A fusion improved the Th1 response induced by
BCG, but it was unable to increase its protective efficacy [Table 1;
Ref. (17)].
Flagellin is another PAMP with potential to be used in fusions
with Mtb antigens. It is recognized by TLR5, a PRR that when
stimulated, induces pro-inflammatory responses as well as the
maturation of APCs, boosting their capacity to activate naïve T
cells to which the cells will present their antigen, thus potentiating
the generation of an efficient adaptive response (52). In addition,
flagellin may also be recognized by other types of PRRs, such as
the Nod-like receptor family CARD 4 (NLRC4) and NIP5 (neu-
ronal apoptosis inhibitory protein 5) (53). The protein p27, a PPE
family protein from Mtb, was fused to the flagellin of E. coli. The
recombinant E. coli expressing p27 in its flagellum was tested in
BALB/c mice and compared with other vaccine strategies, includ-
ing a DNA vaccine, vaccination with purified p27 and Freund’s
adjuvant, and vaccination using a purified protein and CpG DNA.
Immunization with recombinant bacteria induced strong spleno-
cyte proliferation as well as higher induction of IFN-γ [Table 1;
Ref. (19)].
Evidently, the fusion of Mtb antigens with adjuvant molecules
that are agonists of TLR2 and TLR5 can boost the Th1 response.
However, with the exception of L91, the fusions with TLR2 ago-
nists were incapable of generating a protective response superior
to that provided by BCG. In this regard, as described by McBride
et al. (43), mice deficient for TLR2 were not more susceptible
to Mtb when compared with wild-type mice. Another important
aspect of the immune response induced by a vaccine is long-lasting
protection that is provided by the generation of memory cells.
McBride et al. (43) also evaluated the ability of mice that lacked
TLR2 to produce memory cells against TB, and despite the large
number of bacterial antigens that are agonists of this particular
TLR, its absence did not prevent or hinder the generation of this
cell population. However, the fusion of Mtb proteins with PAMPs
may result in conformational changes that diminish the associa-
tion with its cognate PRR, reducing the expected immunological
response. Furthermore, the use of PAMPs must be considered care-
fully, as the immune response induced against the adjuvant fused
to Mtb immune epitopes may result in an enhanced and deleteri-
ous immune response upon infection with Mtb or other pathogens
expressing those PAMPs.
In the case of flagellin use in recombinant live organisms, the
strategy requires that the antigen inserted in the flagellin gene
does not interfere with the final molecule structure, its ability to
transport flagellin, or the final flagellum assembly, which would
compromise the exposure of the molecule on the cellular surface
and the desired goal (52). Live vaccines, such as those includ-
ing Gram-negative bacteria, have other PAMPs (LPS that interacts
with TLR4, peptidoglycan recognized by TLR2, and CpG DNA
recognized by TLR9) and may induce synergistic actions among
PRRs such as TLR5 activation, and overstimulation can occur,
inducing a deleterious inflammatory response.
Heat shock proteins are expressed both constitutively and under
stress conditions in all cells and are essential for several intracellu-
lar processes such as protein transport, protection against denat-
uration and aggregation, and protein folding. Microbial HSPs
(mHSPs) have been described as DAMPs that are highly conserved
between species and potentially immunogenic, with the ability to
induce the production of cytokines and chemokines, increase the
expression of co-stimulatory molecules and activate APCs (partic-
ularly dendritic cells). They have also been shown to be stimulators
of both T cell-mediated and humoral immune responses (54, 55).
Hsp70 from Mtb consists of a 44 kDa ATPase,an 18 kDa domain
that binds to substrate, and a 10 kDa C-terminal fragment (56).
Studies with THP-1 cells indicate that its recognition is mediated
through the interaction of the C-terminal portion and the innate
system, primarily the heterodimer TLR2/TLR4 and CD14 as well
as CD40 and CCR5 (57). This interaction induces the production
of IL-12, TNF-α, CCL5, and reactive oxygen and nitrogen species.
Hsp70 is also recognized by CD8+ T lymphocytes through CD40,
inducing the production of CCL3, CCL4, and CCL5 (56, 58). Based
on these properties, a fusion composed of the C-terminal portion
of Hsp70 (amino acids 359–610) and the immunodominant anti-
gen ESAT-6 was made and tested in BALB/c mice in a subcutaneous
immunization protocol. This fusion vaccine induced an increase
in total IgG specific for ESAT-6 as well as IFN-γ production and
splenocyte proliferation [Table 1; Ref. (21)].
The use of HSPs as vaccines against TB is controversial, as
those proteins are able to induce pro-inflammatory and modu-
latory responses. For instance, Hsp70 from Mtb has been reported
to inhibit the maturation of mouse dendritic cells in vitro and
to modulate effects capable of inducing immune tolerance to
cutaneous allografts through the induction of regulatory T lym-
phocytes (CD4+ CD25+ Foxp3+) (59). In addition, Hsp70 has
also been shown to stimulate the production of IL-10 by peripheral
blood mononuclear cells from patients with arthritis (60). Con-
sequently, despite the capacity to induce IFN-γ production, the
fusion has not been tested for its capacity to generate protection
against Mtb infection, and the production of that cytokine alone
is not sufficient to correlate with protection (61).
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CYTOKINE FUSION WITHMtb PROTEINS AND LIVE
RECOMBINANT VECTORS EXPRESSING CYTOKINES
Cytokines are molecules with biological activities that are pro-
duced by immune system cells and are responsible for cell–cell
communication and the generation of a response following anti-
gen presentation, acting as co-stimulators. Several cytokines are
related to protection against Mtb infection, including TNF-α, IL-
2, IL-6, IL-8, IL-10, and IL-17 among others, thus providing a
different approach for fusion development (3, 62). The fusion of
Mtb antigens to cytokines is aimed at not only modulating the
magnitude of the response but also guiding the development of
the protective immune response. However, cytokine action at the
injection site is part of a complex network of signaling, and the
effects of the administration of a single cytokine may not be the
same as those exercised by the endogenous molecule, which acts
in combination with several other molecules. Additionally, the use
of recombinant cytokines can cause an imbalance of the response,
and in some cases, the systemic administration of cytokines (IL-2,
IL-12, TNF-α, and IFN-γ) has been associated with toxic effects to
the organism. However, the short half-life of several cytokines in
the circulation is also related to the inadequate adjuvant properties
of some of the reported strategies (63).
IL-2 is related to the suppression of Mtb replication through
its participation in T cell maintenance and proliferation as well
as in the activation of NK and γδ T cells to produce IFN-γ. A
fusion protein containing the 65 kDa HSP (Hsp65) and IL-2 was
used in a vaccination scheme (DDA and MPL adjuvants) and
compared to the unfused Hsp65 protein (with DDA and MPL
adjuvants) or BCG. The fusion protein was shown to have a supe-
rior ability to induce the production of IFN-γ and IL-2. Vaccinated
mouse splenocytes were also capable of generating superior cyto-
toxic activity over the P815 cell line (expressing Hsp65-hIL-12).
Last, the protection conferred by the recombinant fusion protein
was similar to that induced by BCG [Table 1; Ref. (24)]. Another
fusion protein, comprising ESAT-6 and IL-2, was inserted in BCG.
BALB/c mice vaccinated with the recombinant bacteria showed
significantly greater induction of ex vivo splenocyte prolifera-
tion and IFN-γ production when stimulated with ESAT-6 and
CFPs (culture filtrate proteins), greater production of total IgG
against ESAT-6 and greater lymphocyte cytotoxic activity. How-
ever, despite the potential immunogenicity, the protection of the
recombinant vaccine was not evaluated (22).
IL-12 has diverse biological functions, as it acts on several
immune system cells. IL-12 plays roles in both the innate and adap-
tive immune responses through JAK-STAT signaling, leading to
effector Th1 cell differentiation and IFN-γ production by CD4+,
NK, and NKT cells in the initial stages of infection (Figure 1)
(64, 65). The influence of IL-12 on CD8+ T cell differentiation
has also been demonstrated through its action as the third signal
(66). In addition, this cytokine acts on B cells, favoring IgG2a class
switching and inhibiting IgE and IgG1 (67). A recombinant BCG
containing a fusion of the IL-12p70 and ESAT-6 genes was shown
to induce higher IFN-γ production than the other BCG constructs
analyzed (BCG, rBCG-ESAT-6, and rBCG-IL-12), as well as higher
total IgG, IgG1, and IgG2a levels. However, none of the recombi-
nant constructs surpassed the protection induced by wild-type
BCG [Table 1; Ref. (25)].
IL-15 is an important cytokine in the immune response of
CD8+ T lymphocytes, as it is involved in clonal expansion, mem-
ory cell (CD44hi) generation, and antigen recognition, and it
further acts as a T lymphocyte chemoattractant (Figure 1) (68,
69). A fusion protein was designed to explore the poor CD8+ T
cell stimulation capacity of BCG (70); the fusion protein com-
prised Ag85B and IL-15 and was expressed in BCG [Table 1; Ref.
(23)]. The recombinant BCG was shown to enhance the con-
trol of infection, inducing total memory (CD44+) CD4+ and
CD8+ T cells, and to potentiate the production of IFN-γ by both
CD4 and CD8 T cells. Finally, the presence of IL-15 was capa-
ble of enhancing the protection against Mtb when compared with
rBCG-Ag85B, with lower bacillary loads in the lungs and milder
pathology (23).
Granulocyte macrophage colony-stimulating factor (GM-CSF)
has several described biological effects, but from the vaccination
perspective, its primary effects are enhancement of the matura-
tion, migration, and immunostimulatory properties of Langer-
hans, dendritic, and NK cells; increasing MHC class II expression
on APCs, which plays a fundamental role in antigen presentation
to CD4 T helper cells; increasing the expression of CD80, a co-
stimulatory molecule that participates in T lymphocyte activation,
on Langerhans giant cells in vitro; and inducing local inflammation
at the injection site, resulting in the accumulation of neutrophils
and mononuclear cells (Figure 1). An important role of GM-CSF
has also been demonstrated in mice lacking GM-CSF expression,
which were more susceptible to Mtb infection (71). In one study,
GM-CSF was fused to ESAT-6, and the recombinant fusion gene
was inserted into BCG, creating rBCG:GE. This rBCG was tested
and compared to BCG expressing either ESAT-6 (rBCG:E) or GM-
CSF (rBCG:G). rBCG:GE induced higher levels of total IgG, IgG1,
and IgG2a. Mice immunized with rBCG:GE also had higher levels
of specific CD4+ and CD8+ T cells 8 weeks after immunization
when compared with the other recombinant BCG vaccines. Last,
rBCG:GE also showed the greatest capacity to stimulate IFN-γ
production by the splenocytes of immunized mice. However, no
protection assay was described by the authors [Table 1; Ref. (26)].
When using cytokines as immune stimulation components in
vaccines, one expects that they will enhance the immune response
due to their participation in the regulation of both innate and
adaptive immune responses. In the published literature, IL-2, IL-
12, IL-15, and GM-CSF have been reported as potential immune
response stimulators. However,only the Hsp65 antigen fusion with
IL-2 was used without being in the context of the BCG vector,
and in that case, it was necessary to use a dimethyl dioctadecyl
ammonium bromide (DDA) and MPL emulsion as an adjuvant to
generate an efficient immune response, demonstrating the inabil-
ity of a single cytokine to support an antigen-elicited response.
Although fusions of Mtb antigens with cytokines have been shown
to be immunogenic and to improve the response to BCG, only one
of the studies we reviewed, using IL-15/Ag85B, induced levels of
protection against bacteria that were better than those induced by
the current vaccine. Additionally, two studies did not evaluate the
protection against Mtb, which prevents a more thorough assess-
ment of the real potential of the examined fusion vaccines because
there is no consensus in the scientific community of a biomarker
for protection.
Frontiers in Immunology | Microbial Immunology April 2014 | Volume 5 | Article 188 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Junqueira-Kipnis et al. Subunits Mtb vaccines fusioned with adjuvants
Among the major obstacles faced in the search for adjuvants
capable of stimulating Th1 type responses is the immunotoxic-
ity generated by some molecules. Therefore, an adjuvant should
be effective in assisting the generation of protective immune
responses while inducing few side effects (72). However, the bal-
ance between effectiveness and toxicity in a vaccine for TB is
complex because the protective immune response against the agent
(Th1 and Th17) is highly inflammatory. Side effects related to the
use of adjuvants can be divided into two major groups: local and
systemic effects. The most common effects are local injection site
tenderness and swelling, while the more severe reactions involve
the formation of abscesses and painful nodules. With regard to
systemic effects, the most common reaction is a non-specific acute
phase reaction, characterized by changes in plasma proteins, fever,
fatigue, and anorexia, whereas severe effects may include the gen-
eration of autoimmune diseases or worsening thereof and the
appearance of neurological disorders (73). Systemic side effects
related to the administration of adjuvants typically prevent their
use in human vaccines, and these effects usually occur due to
the hyperactivation of the immune system as a result of constant
exposure to adjuvant, which causes an intense production of pro-
inflammatory cytokines (IL-1, IL-6, TNF-α, IFN-γ, and others).
Importantly, these effects may occur after the administration of a
cytokine adjuvant or after the use of a molecule and subsequent
infection by a microorganism that has the same molecule in its
constitution, and therefore, such effects must be considered when
choosing an adjuvant for a vaccine formulation (73, 74).
CONCLUSION
Several fusions of Mtb proteins or immunodominant epitopes
have been evaluated as subunit vaccines for TB. Some adjuvants
have been incorporated in the vaccine formulation without a phys-
ical association with the recombinant fusion proteins, while others
have been incorporated in the backbone of the subunit vaccines.
Other studies have evaluated recombinant BCG vaccines express-
ing both Mtb proteins and adjuvant molecules. The majority of
the vaccine formulations were able to induce higher levels of Th1
and IgG2a responses, although not all of the vaccines discussed
here presented better protection against Mtb than BCG.
The fusion of Mtb antigens with adjuvants can interfere with
the induction of specific immune responses, but in most of the
reviewed articles, the vaccine formulations did not offer improve-
ments over the protection conferred by BCG. Thus, further studies
are needed to develop an effective adjuvant with low toxicity to be
used in vaccine formulations to control TB.
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